The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Open accessAbstract
IMPORTANCE: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE: To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).16”
From Type 1 diabetes (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most individuals without diabetes who have only one autoantibody will not develop type 1 diabetes, as the 10-year risk is about 15% (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a nearcertain predictor of clinical diabetes (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a near-certain predictor of clinical diabetes (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A seminal analysis of four different birth cohorts from the USA, Finland and Germany demonstrated that the presence of a single islet autoantibody is associated with a 13% risk of developing type 1 diabetes over 15 years. In contrast, having two or more antibodies is associated with a 70% risk over 10 years of observation and an 84% risk over 15 years63.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, studies of the offspring of people with diabetes show that young children with multiple autoantibodies develop diabetes during childhood [ 12 ]”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“In children with only one persistent islet autoantibody, the risk of diabetes within 10 years is 15% while two or more islet autoantibodies predict type 1 diabetes in 70% within 10 years (408,409).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Self-citationGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Self-citationQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes
Bonifacio, E. E., Shattock, M., Dean, B. M., Bottazzo, G. F., Bingley, P. J., Gale, E., & Dunger, D. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)90013-u · Cited by 344
Self-citationStratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E. E., & Ziegler, A. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 276
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationPREDICTING INSULIN-DEPENDENT DIABETES
Tarn, A., Dean, B., Schwarz, G., Thomas, J. M., Ingram, D., Bottazzo, G. F., & Gale, E. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91601-7 · Cited by 260
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,001
OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis
Helminen, O., Aspholm, S., Pokka, T. M.-L., Ilonen, J., Simell, O., Veijola, R., & Knip, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3621-9 · Cited by 57
Self-citationA novel LIPS assay for insulin autoantibodies
Liberati, D., Wyatt, R. C., Brigatti, C., Marzinotto, I., Ferrari, M., Bazzigaluppi, E., Bosi, E., Gillard, B. T., Gillespie, K. M., Gorus, F., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-017-1082-y · Cited by 57
Steck, A. K., Larsson, H. E., Liu, X., Veijola, R., Toppari, J., Hagopian, W. A., Haller, M. J., Ahmed, S., Akolkar, B., Lernmark, Å., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12485 · Cited by 56
Self-citationDe Jesus, D. F., Zhang, Z., Brown, N. K., Li, X., Xiao, L., Hu, J., Gaffrey, M. J., Fogarty, G., Kahraman, S., Wei, J., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01368-0 · Cited by 56
Metabolic alterations in immune cells associate with progression to type 1 diabetes
Sen, P., Dickens, A. M., López-Bascón, M. A., Lindeman, T., Kemppainen, E., Lamichhane, S., Rönkkö, T., Ilonen, J., Toppari, J., Veijola, R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05107-6 · Cited by 56
Self-citationNeoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets
Calvo, T. R., Johnson, J. D., Overbergh, L., & Dunne, J. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667989 · Cited by 58
Pancreas Pathology During the Natural History of Type 1 Diabetes
Calvo, T. R., Richardson, S. J., & Pugliese, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1084-3 · Cited by 54
Perinatal risk factors for type 1 diabetes revisited: a population-based register study
Waernbaum, I., Dahlquist, G. G., & Lind, T. (2019) · Diabetologia · doi:10.1007/s00125-019-4874-5 · Cited by 57
Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes
Lamichhane, S., Sen, P., Dickens, A. M., Alves, M. A., Härkönen, T., Honkanen, J. K., Vatanen, T., Xavier, R. J., Hyötyläinen, T., Knip, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100762 · Cited by 58
Self-citationThompson, W. S., Pękalski, M. Ł., Simons, H. Z., Smyth, D. J., Dopico, X. C., Guo, H., Guy, C., Dunger, D. B., Arif, S., Peakman, M., et al. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12362 · Cited by 56
Bonifacio, E. E., Weiß, A., Winkler, C., Hippich, M., Rewers, M., Toppari, J., Lernmark, Å., She, J., Hagopian, W., Krischer, J. P., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2122 · Cited by 57
Self-citationDiagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-8963 · Cited by 60
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study
Knip, M., Parviainen, A., Turtinen, M., But, A., Härkönen, T., Hepojoki, J., Sironen, T. A., Iheozor-Ejiofor, R. P., Uğurlu, H., Saksela, K., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00041-4 · Cited by 53
Self-citationViruses and Type 1 Diabetes: From Enteroviruses to the Virome
Isaacs, S. R., Foskett, D. B., Maxwell, A. J., Ward, E. J., Faulkner, C. L., Luo, J. Y. X., Rawlinson, W. D., Craig, M. E., & Kim, K. W. (2021) · Microorganisms · doi:10.3390/microorganisms9071519 · Cited by 53
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 72
Serum Trypsinogen Levels in Type 1 Diabetes
Li, X., Campbell‐Thompson, M., Wasserfall, C. H., MCGRAIL, K. M., Posgai, A. L., Schultz, A., Brusko, T. M., Shuster, J. J., Liang, F., MUIR, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1774 · Cited by 52
Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes
Ostrov, D. A., Alkanani, A. K., McDaniel, K. A., Case, S. R., Baschal, E. E., Pyle, L. L., Ellis, S., Pöllinger, B., Seidl, K. J., Shah, V. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97739 · Cited by 54
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Greenbaum, C. J., VanBuecken, D., & Lord, S. M. (2019) · Drugs · doi:10.1007/s40265-018-1035-y · Cited by 56
Ross, C., Ward, Z. J., Gomber, A., Owais, M., Yeh, J. M., Reddy, C.-L., & Atun, R. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.815703 · Cited by 52
Reduced β-cell function in early preclinical type 1 diabetes
Koskinen, M. K., Helminen, O., Matomäki, J., Aspholm, S., Mykkänen, J., Mäkinen, M., Simell, V., Vähä-Mäkilä, M., Simell, T. T., Ilonen, J., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0674 · Cited by 51
Self-citationPöllänen, P. M., Lempainen, J., Laine, A., Toppari, J., Veijola, R., Vähäsalo, P., Ilonen, J., Siljander, H., & Knip, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4258-7 · Cited by 51
Self-citationTargeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes
Bagge, S. L., Fotheringham, A. K., Leung, S. S., & Forbes, J. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21654 · Cited by 54
Fungal Dysbiosis and Intestinal Inflammation in Children With Beta-Cell Autoimmunity
Honkanen, J. K., Vuorela, A., Muthas, D., Orivuori, L., Luopajärvi, K., Tejesvi, M. V., Lavrinienko, A., Pirttilä, A. M., Fogarty, C. L., Härkönen, T., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00468 · Cited by 51
Self-citationFelton, J. L., REDONDO, M. J., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Harris-Kawano, A., Perez, D., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00478-y · Cited by 63
Chmiel, R., Giannopoulou, E. Z., Winkler, C., Achenbach, P., Ziegler, A., & Bonifacio, E. E. (2014) · Diabetologia · doi:10.1007/s00125-014-3443-1 · Cited by 50
Self-citationSteck, A. K., Dong, F., Taki, I., Hoffman, M., KLINGENSMITH, G. J., & Rewers, M. (2014) · Diabetes Care · doi:10.2337/dc13-2965 · Cited by 50
Self-citationZhao, Z., Miao, D., Michels, A. W., Steck, A. K., Dong, F., Rewers, M., & Yu, L. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.01.011 · Cited by 52
Self-citationDietary Cows’ Milk Protein A1 Beta-Casein Increases the Incidence of T1D in NOD Mice
Chia, J. S., McRae, J. L., Enjapoori, A. K., Lefèvre, C. M., Kukuljan, S., & Dwyer, K. M. (2018) · Nutrients · doi:10.3390/nu10091291 · Cited by 52
The case for an autoimmune aetiology of type 1 diabetes
Mannering, S. I., Pathiraja, V., & Kay, T. W. H. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12699 · Cited by 51
Unanue, E. R., Ferris, S. T., & Carrero, J. A. (2016) · Immunological Reviews · doi:10.1111/imr.12430 · Cited by 49
Epigenetics and type 1 diabetes: mechanisms and translational applications
Zullo, A., Sommese, L., Nicoletti, G., Donatelli, F., Mancini, F. P., & Claudio Napoli, A. (2017) · Translational research · doi:10.1016/j.trsl.2017.05.002 · Cited by 49
Orešič, M., McGlinchey, A. J., Wheelock, C. E., & Hyötyläinen, T. (2020) · Metabolites · doi:10.3390/metabo10110454 · Cited by 52
Jacobsen, L. M., Larsson, H. E., Tamura, R. N., Vehik, K., Clasen, J., Sosenko, J., Hagopian, W. A., She, J., Steck, A. K., Rewers, M., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12812 · Cited by 48
Self-citationWasserfall, C. H., Montgomery, E., Yu, L., Michels, A. W., Gianani, R., Pugliese, A., Nierras, C. R., Kaddis, J. S., Schatz, D., Bonifacio, E. E., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12797 · Cited by 48
Self-citation3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood
Ziegler, A., Haupt, F., Scholz, M., Weininger, K., Wittich, S., Löbner, S., Matzke, C., Gezginci, C., Riethausen, S., Beyerlein, A., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0199 · Cited by 48
Self-citationAmoroso, M., Achenbach, P., Powell, M. J., Coles, R. L., Chlebowska, M., Carr, L., Furmaniak, J., Scholz, M., Bonifacio, E. E., Ziegler, A., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.08.013 · Cited by 48
Self-citationTranscriptional networks in at-risk individuals identify signatures of type 1 diabetes progression
Xhonneux, L.-P., Knight, O., Lernmark, Å., Bonifacio, E. E., Hagopian, W., Rewers, M., She, J., Toppari, J., Parikh, H. M., Smith, K. G. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd5666 · Cited by 48
Self-citationGeneral population screening for type 1 diabetes
Insel, R. A., Dunne, J. L., & Ziegler, A. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000173 · Cited by 49
Self-citationT-cell responses to hybrid insulin peptides prior to type 1 diabetes development
Mitchell, A. M., Alkanani, A. K., McDaniel, K. A., Pyle, L. L., Waugh, K., Steck, A. K., Nakayama, M., Yu, L., Gottlieb, P. A., Rewers, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019129118 · Cited by 50
Self-citationKrause, S., Landherr, U., Agardh, C., Hausmann, S., Link, K., Hansen, J. M., Lynch, K. F., Powell, M. J., Furmaniak, J., Rees-Smith, B., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1719 · Cited by 47
Self-citationLiu, C., Bramer, L., Webb‐Robertson, B., Waugh, K., Rewers, M., & Zhang, Q. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.10.004 · Cited by 44
Self-citationEthnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk
the Type 1 Diabetes TrialNet Study Group, Tosur, M., Geyer, S. M., Rodriguez, H., Libman, I. M., Baidal, D. A., & REDONDO, M. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4660-9 · Cited by 47
Hippich, M., Beyerlein, A., Hagopian, W., Krischer, J. P., Vehik, K., Knoop, J., Winker, C., Toppari, J., Lernmark, Å., Rewers, M., et al. (2019) · Diabetes · doi:10.2337/db18-0882 · Cited by 48
Self-citationMonar, G. V. F., Islam, H., Puttagunta, S. M., Islam, R., Kundu, S., Jha, S. B., Rivera, A. P., & Sange, I. (2022) · Cureus · doi:10.7759/cureus.22912 · Cited by 50
Larsson, P. G., Lakshmikanth, T., Laitinen, O. H., Utorova, R., Jacobson, S., Oikarinen, M., Domsgen, E., Koivunen, M. R. L., Chaux, P., Devard, N., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3436-0 · Cited by 48
Self-citationPecheur, A., Barrea, T., Vandooren, V., Beauloye, V., Robert, A. R., & Lysy, P. A. (2014) · Journal of Diabetes Research · doi:10.1155/2014/851378 · Cited by 47
Greenbaum, C. J., Speake, C., Krischer, J. P., Buckner, J. H., Gottlieb, P. A., Schatz, D., Herold, K. C., & Atkinson, M. A. (2018) · Diabetes · doi:10.2337/db18-0065 · Cited by 49
Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance
Gaglia, J. L., & Kissler, S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00707 · Cited by 47
Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis
Shapiro, M. R., Wasserfall, C. H., McGrail, S., Posgai, A. L., Bacher, R. L., MUIR, A. B., Haller, M. J., Schatz, D., Wesley, J. D., von Herrath, M., et al. (2019) · Diabetes · doi:10.2337/db19-0942 · Cited by 47
Cortez, F. D. J., Gebhart, D., Robinson, P. V., Seftel, D., Pourmandi, N., Owyoung, J., Bertozzi, C. R., Wilson, D. M., Maahs, D. M., Buckingham, B. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242049 · Cited by 46
Bélteky, M., Milletich, P. L., Ahrens, A. P., Triplett, E. W., & Ludvigsson, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05895-7 · Cited by 44
Islet Microvasculature Alterations With Loss of Beta-cells in Patients With Type 1 Diabetes
Canzano, J. S., Nasif, L., Butterworth, E., Fu, D.-T. A., Atkinson, M., & Campbell-Thompson, M. (2018) · Journal of Histochemistry and Cytochemistry · doi:10.1369/0022155418778546 · Cited by 35
Endesfelder, D., zu Castell, W., Bonifacio, E. E., Rewers, M., Hagopian, W., She, J., Lernmark, Å., Toppari, J., Vehik, K., Williams, A. J. K., et al. (2018) · Diabetes · doi:10.2337/db18-0594 · Cited by 45
Self-citationType 1 Diabetes-related Autoantibodies in Different Forms of Diabetes
Sørgjerd, E. P. (2019) · Current Diabetes Reviews · doi:10.2174/1573399814666180730105351 · Cited by 47
General population screening for childhood type 1 diabetes: is it time for a UK strategy?
Besser, R. E. J., Ng, S. M., Gregory, J. W., Dayan, C. M., Randell, T. L., & Barrett, T. G. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-321864 · Cited by 49
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 46
Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetes
Giovenzana, A., Carnovale, D., Phillips, B. E., Petrelli, A., & Giannoukakis, N. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3483 · Cited by 44
Type 1 Diabetes and Its Multi-Factorial Pathogenesis: The Putative Role of NK Cells
Marca, V. L., Gianchecchi, E., & Fierabracci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030794 · Cited by 46
Lund‐Blix, N. A., Dong, F., Mårild, K., Seifert, J. A., Barón, A. E., Waugh, K., Joner, G., Størdal, K., Tapia, G., Stene, L. C., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2315 · Cited by 49
Self-citationEvolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44
Benkahla, M. A., Sabouri, S., Kiosses, W. B., Rajendran, S. H., Quesada‐Masachs, E., & von Herrath, M. G. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102628 · Cited by 42
Wiberg, A., Granstam, A., Ingvast, S., Härkönen, T., Knip, M., Korsgren, O., & Skog, O. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12698 · Cited by 45
Self-citationIncomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin
Ashton, M. P., Eugster, A., Walther, D., Daehling, N., Riethausen, S., Kuehn, D., Klingel, K., Beyerlein, A., Zillmer, S., Ziegler, A., et al. (2016) · Scientific Reports · doi:10.1038/srep32899 · Cited by 43
Self-citationStrollo, R., Vinci, C., Napoli, N., Pozzilli, P., Ludvigsson, J., & Nissim, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4296-1 · Cited by 43
Inshaw, J. R. J., Walker, N. M., Wallace, C., Bottolo, L., & Todd, J. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4440-y · Cited by 41
Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes
Felton, J. L., Maseda, D., Bonami, R. H., Hulbert, C., & Thomas, J. W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701717 · Cited by 43
Gu, Y., Zhao, Z., Waugh, K., Miao, D., Jia, X., Cheng, J., Michels, A. W., Rewers, M., Yang, T., & Yu, L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.036 · Cited by 43
Self-citationJohnson, M. B., Patel, K., Franco, E. D., Hagopian, W., Killian, M., McDonald, T. J., Tree, T. I. M., Domingo‐Vila, C., Hudson, M., Hammersley, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05276-4 · Cited by 43
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42
Self-citationClair, J. R. S., Ramirez, D. G., Passman, S., & Benninger, R. K. P. (2018) · Nature Communications · doi:10.1038/s41467-018-03953-y · Cited by 42
Immune Mechanisms and Pathways Targeted in Type 1 Diabetes
Jacobsen, L. M., Newby, B. N., Perry, D. J., Posgai, A. L., Haller, M. J., & Brusko, T. M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1066-5 · Cited by 42
Bauer, W., Veijola, R., Lempainen, J., Kiviniemi, M., Härkönen, T., Toppari, J., Knip, M., Gyenesei, A., & Ilonen, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00421 · Cited by 43
Self-citationThe elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes
Bloem, S. J., & Roep, B. O. (2017) · Diabetologia · doi:10.1007/s00125-017-4284-5 · Cited by 42
Kwon, B. C., Anand, V., Achenbach, P., Dunne, J. L., Hagopian, W., Hu, J., Koski, E., Lernmark, Å., Lundgren, M., Ng, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28909-1 · Cited by 43
Self-citationDiagnóstico do diabetes e rastreamento do diabetes tipo 2
Cobas, R. A., Rodacki, M., Giacaglia, L. R., Calliari, L. E., de Noronha, R. M., Valério, C. M., Custódio, J., Scharf, M., Barcellos, C. R. G., Tomarchio, M. P., et al. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-2 · Cited by 96
Hendriks, E., Marcovecchio, M. L., Besser, R. E. J., Bonifacio, E. E., Casteels, K., Larsson, H. E., Gemulla, G., Lundgren, M., Kordonouri, O., Mallone, R., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3777 · Cited by 41
Self-citationCherubini, V., Mozzillo, E., Iafusco, D., Bonfanti, R., Ripoli, C., Pricci, F., Vincentini, O., Agrimi, U., Silano, M., Ulivi, F., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15779 · Cited by 41
Endesfelder, D., Hagen, M., Winkler, C., Haupt, F., Zillmer, S., Knopff, A., Bonifacio, E. E., Ziegler, A., zu Castell, W., & Achenbach, P. (2016) · Diabetologia · doi:10.1007/s00125-016-4050-0 · Cited by 43
Self-citationHelminen, O., Pokka, T. M.-L., Tossavainen, P. H., Ilonen, J., Knip, M., & Veijola, R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.027 · Cited by 42
Self-citationThe gut microbiota in type 1 diabetes: friend or foe?
Gavin, P. G., & Hamilton‐Williams, E. E. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000483 · Cited by 42
Circulating metabolites in progression to islet autoimmunity and type 1 diabetes
Lamichhane, S., Kemppainen, E., Trôst, K., Siljander, H., Hyöty, H., Ilonen, J., Toppari, J., Veijola, R., Hyötyläinen, T., Knip, M., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-04980-0 · Cited by 42
Self-citationDysregulation of glucose metabolism in preclinical type 1 diabetes
Veijola, R., Koskinen, M. K., Helminen, O., & Hekkala, A. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12392 · Cited by 41
Self-citationCiężki, S., Kurpiewska, E., Bossowski, A. T., & Głowińska‐Olszewska, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.890833 · Cited by 47
Predictors of slow progression to diabetes in children with multiple islet autoantibodies
Steck, A. K., Dong, F., Waugh, K., Frohnert, B. I., Yu, L., Norris, J. M., & Rewers, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.05.010 · Cited by 40
Self-citationUnderstanding Pre-Type 1 Diabetes: The Key to Prevention
Jacobsen, L. M., Haller, M. J., & Schatz, D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00070 · Cited by 40
Clinical and research uses of genetic risk scores in type 1 diabetes
Sharp, S. A., Weedon, M. N., Hagopian, W., & Oram, R. A. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.03.009 · Cited by 43
Diabetes: a review of its pathophysiology, and advanced methods of mitigation
Gupta, S., Sharma, N., Arora, S., & Verma, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2333440 · Cited by 41
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
Nathan, B. M., Boulware, D. C., Geyer, S. M., Atkinson, M. A., Colman, P. G., Goland, R., Russell, W. E., Wentworth, J. M., Wilson, D. M., Evans‐Molina, C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0916 · Cited by 38
Long, A. E., Wilson, I. V., Becker, D. J., Libman, I. M., Arena, V. C., Wong, F. S., Steck, A. K., Rewers, M., Yu, L., Achenbach, P., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4591-5 · Cited by 41
Self-citationCommon ground: shared risk factors for type 1 diabetes and celiac disease
Verdu, E. F., & Danska, J. S. (2018) · Nature Immunology · doi:10.1038/s41590-018-0130-2 · Cited by 39
Triolo, T. M., Fouts, A., Pyle, L., Yu, L., Gottlieb, P. A., Steck, A. K., Type 1 Diabetes TrialNet Study Group, Greenbaum, C. J., Atkinson, M. A., Baidal, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0288 · Cited by 39
Self-citationBeyerlein, A., Bonifacio, E. E., Vehik, K., Hippich, M., Winkler, C., Frohnert, B. I., Steck, A. K., Hagopian, W., Krischer, J. P., Lernmark, Å., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105532 · Cited by 40
Self-citationLand Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes
Nurminen, N., Cerrone, D., Lehtonen, J., Parajuli, A., Roslund, M. I., Lönnrot, M., Ilonen, J., Toppari, J., Veijola, R., Knip, M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1719 · Cited by 46
Self-citationJin, Y., Sharma, A. K., Bai, S., Davis, C., Liu, H., Hopkins, D., Barriga, K., Rewers, M., & She, J. (2014) · Diabetes · doi:10.2337/db13-1716 · Cited by 39
Self-citationT Cell Receptor Profiling in Type 1 Diabetes
Jacobsen, L. M., Posgai, A. L., Seay, H. R., Haller, M. J., & Brusko, T. M. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0946-4 · Cited by 38
Metabolite-related dietary patterns and the development of islet autoimmunity
Johnson, R. K., Vanderlinden, L. A., DeFelice, B. C., Kechris, K. J., Uusitalo, U. M., Fiehn, O., Sontag, M. K., Crume, T., Beyerlein, A., Lernmark, Å., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51251-4 · Cited by 37
Self-citationZiegler, A., Arnolds, S., Koelln, A., Achenbach, P., Berner, R., Bonifacio, E. E., Casteels, K., Larsson, H. E., Gündert, M., Hasford, J., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052449 · Cited by 42
Self-citationPreclinical Inflammatory Rheumatic Diseases
Raza, K., & Gerlag, D. M. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.07.001 · Cited by 38
Juusola, M., Parkkola, A., Härkönen, T., Siljander, H., Ilonen, J., Åkerblom, H. K., Knip, M., & the Childhood Diabetes in Finland Study Group (2015) · Diabetes Care · doi:10.2337/dc15-1027 · Cited by 38
Self-citation
Metadata
- Authors
- Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., Bonifacio, E., & Eisenbarth, G. S.
- Affiliations
- TUM Klinikum (DE)
- University of Helsinki (FI)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-19
- Volume
- 309
- Issue
- 23
- Pages
- 2473
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4878912
- OpenAlex
- W2095256598
- Semantic Scholar
- 5a7a8cb24a1d4a727e23b19c717a8328b3ce09d6
- Cited by
- 1,312
- References
- 29
- Citations by year
- 2026: 118 · 2025: 133 · 2024: 103 · 2023: 124 · 2022: 107 · 2021: 127 · 2020: 83 · 2019: 92 · 2018: 92 · 2017: 86 · 2016: 89 · 2015: 83 · 2014: 55 · 2013: 18
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Juvenile Diabetes Research Foundation International (4‐1999‐731, 4‐2001‐435)
- Deutsche Forschungsgemeinschaft (/14-2, /14-1)
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Lastentautien Tutkimussäätiö
- National Institutes of Health (DK32493)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK32493, R01DK032493, U01DK063821)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, seroconversion, multiple autoantibodies, progression to diabetes, insulin autoantibodies, GAD65 antibodies, IA-2 autoantibodies, preclinical diabetes, risk prediction, age at seroconversion, islet transplantation
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Diabetes Mellitus, Type 1, Female, Finland, Follow-Up Studies, Genotype, Germany, Glutamate Decarboxylase, Humans, Infant, Insulin, Islets of Langerhans, Male, Prospective Studies, Risk, Disease Progression, Genetic Predisposition to Disease, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
